These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22215904)

  • 21. Targeting MAPK pathway in melanoma therapy.
    Cheng Y; Zhang G; Li G
    Cancer Metastasis Rev; 2013 Dec; 32(3-4):567-84. PubMed ID: 23584575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
    Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
    J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [ASCO highlights in the treatment of metastatic melanoma].
    Hertlein A
    Med Monatsschr Pharm; 2014 May; 37(5):183-4. PubMed ID: 24908933
    [No Abstract]   [Full Text] [Related]  

  • 24. The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications.
    Haluska F; Pemberton T; Ibrahim N; Kalinsky K
    Semin Oncol; 2007 Dec; 34(6):546-54. PubMed ID: 18083378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?
    Passeron T; Lacour JP; Allegra M; Ségalen C; Deville A; Thyss A; Giacchero D; Ortonne JP; Bertolotto C; Ballotti R; Bahadoran P
    Exp Dermatol; 2011 Dec; 20(12):1030-2. PubMed ID: 22092579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options.
    Villanueva J; Vultur A; Herlyn M
    Cancer Res; 2011 Dec; 71(23):7137-40. PubMed ID: 22131348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas.
    Sviatoha V; Tani E; Ghaderi M; Kleina R; Skoog L
    Anticancer Res; 2010 Sep; 30(9):3267-72. PubMed ID: 20944096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
    Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
    Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of BRAF in thyroid oncogenesis.
    Caronia LM; Phay JE; Shah MH
    Clin Cancer Res; 2011 Dec; 17(24):7511-7. PubMed ID: 21900390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New drug targets in metastatic melanoma.
    Homet B; Ribas A
    J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
    Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
    Clin Cancer Res; 2003 Dec; 9(17):6483-8. PubMed ID: 14695152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Promising Strategies for Overcoming BRAF Inhibitor Resistance Based on Known Resistance Mechanisms.
    Li QS; Shen BN; Xu HJ; Ruan BF
    Anticancer Agents Med Chem; 2020; 20(12):1415-1430. PubMed ID: 32321411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospects for non-immunological molecular therapeutics in melanoma.
    Eustace AJ; Mahgoub T; Tryfonopoulos D; O'Donovan N; Crown J
    J BUON; 2010; 15(1):9-18. PubMed ID: 20414921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual inhibition of (V600E)BRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism.
    Sánchez-Hernández I; Baquero P; Calleros L; Chiloeches A
    Cancer Lett; 2012 Jan; 314(2):244-55. PubMed ID: 22056813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in targeted therapy for melanoma.
    Friedlander P; Hodi FS
    Clin Adv Hematol Oncol; 2010 Sep; 8(9):619-27. PubMed ID: 21157411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The new arms race against melanoma.
    Lejeune FJ
    Melanoma Res; 2006 Feb; 16(1):1-2. PubMed ID: 16432449
    [No Abstract]   [Full Text] [Related]  

  • 37. [The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice].
    Zafon C; Obiols G
    Endocrinol Nutr; 2009 Apr; 56(4):176-86. PubMed ID: 19627734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells.
    Sala E; Mologni L; Truffa S; Gaetano C; Bollag GE; Gambacorti-Passerini C
    Mol Cancer Res; 2008 May; 6(5):751-9. PubMed ID: 18458053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRAF inhibitors: research accelerates in wake of positive findings.
    Brower V
    J Natl Cancer Inst; 2010 Feb; 102(4):214-5. PubMed ID: 20145213
    [No Abstract]   [Full Text] [Related]  

  • 40. Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma.
    Patel SP; Kim KB
    Expert Opin Investig Drugs; 2012 Apr; 21(4):531-9. PubMed ID: 22394161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.